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Abstract
Background: The formation of metastasis is the most common cause of death in patients with lung cancer. A major 
implement to understand the molecular mechanisms involved in lung cancer metastasis has been the lack of suitable 
models to address it. In this study, we aimed at establishing a highly metastatic model of human lung cancer and 
characterizing its metastatic properties and underlying mechanisms.
Methods: The human lung adeno-carcinoma SPC-A-1 cell line was used as parental cells for developing of highly 
metastatic cells by in vivo selection in NOD/SCID mice. After three rounds of selection, a new SPC-A-1sci cell line was 
established from pulmonary metastatic lesions. Subsequently, the metastatic properties of this cell line were analyzed, 
including optical imaging of in vivo metastasis, immunofluorescence and immunohistochemical analysis of several 
epithelial mesenchymal transition (EMT) makers and trans-well migration and invasion assays. Finally, the functional 
roles of fibronectin in the invasive and metastatic potentials of SPC-A-1sci cells were determined by shRNA analysis.
Results: A spontaneously pulmonary metastatic model of human lung adeno-carcinoma was established in NOD/
SCID mice, from which a new lung cancer cell line, designated SPC-A-1sci, was isolated. Initially, the highly metastatic 
behavior of this cell line was validated by optical imaging in mice models. Further analyses showed that this cell line 
exhibit phenotypic and molecular alterations consistent with EMT. Compared with its parent cell line SPC-A-1, SPC-A-
1sci was more aggressive in vitro, including increased potentials for cell spreading, migration and invasion. Importantly, 
fibronectin, a mesenchymal maker of EMT, was found to be highly expressed in SPC-A-1sci cells and down-regulation 
of it can decrease the in vitro and in vivo metastatic abilities of this cell line.
Conclusions: We have successfully established a new human lung cancer cell line with highly metastatic potentials, 
which is subject to EMT and possibly mediated by increased fibronectin expression. This cell line and its reproducible 
s.c. mouse model can further be used to identify underlying mechanisms of lung cancer metastasis.
Background
According to the World Health Organization, lung cancer
is responsible for more than 1.3 billion deaths worldwide
annually. Despite advances in the treatment of primary
tumours, recurrence and metastasis are the most com-
mon cause of death in patients with lung cancer. The cur-
rent poor understanding of the molecular mechanisms
involved in lung cancer metastasis is due, in large part, to
the lack of suitable models for its study [1,2]. Although
many metastatic models have been successfully used to
identify molecular elements during metastasis, most rely
on the introduction of tumour cells directly into the sys-
temic circulation. These models do not represent the
steps of detachment of tumour cells from the primary
tumour--invasion and intravasation--and therefore are
unlikely to reveal genes involved in these early steps of
metastasis [3,4]. A metastatic model that can represent
the full spectrum of metastasis is rare, especially for lung
cancer, so it is necessary to develop a spontaneously met-
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astatic model of human lung cancer, so as to provide a
platform for uncovering the underlying mechanisms.
EMT, a process whereby cells acquire molecular altera-
tions that facilitate cell motility and invasion, has been
shown to play an important role in tumour metastasis [5].
More recently, there are also observations suggesting that
the EMT program exists in lung cancer and correlates
with the poor prognosis of patients with lung cancer
[6,7]. However, these works are mostly based on cultured
cell models, and the precise roles of EMT in lung cancer
metastasis are still largely unclear. Metastases ultimately
develop in secondary organ sites as a consequence of the
interactions between tumour cells and the host microen-
vironment [8]. Fibronectin, a glycoprotein in extracellular
matrix and also a mesenchymal maker of EMT, has been
implicated in the development of multiple types of
human cancer [9,10]. In lung cancer, fibronectin expres-
sion is increased and has been implicated in promoting
lung cancer growth and conferring resistance to therapy
[11,12]. In addition, fibronectin has been shown to pro-
mote lung cancer cell migration and invasion by increas-
ing MMP-9 expression or activating FAK signaling
[13,14]. However, the specific role and molecular basis of
fibronectin in lung cancer metastasis are still elusive.
In the present report, we successfully develop a sponta-
neously metastatic model of human lung cancer that rep-
resents the full spectrum of metastasis, from which a
highly metastatic human lung cancer cell line, termed
SPC-A-1sci, was derived. This cell line exhibits typical
changes in cellular phenotype similar to EMT. Moreover,
fibronectin plays an important role in these alterations,
and thus resulting in the highly metastatic potentials of
this cell line.
Methods
Cell lines and cell culture
The human lung adeno-carcinoma cell line SPC-A-1 was
obtained from Cellular Institute of Chinese Academy of
Science (Shanghai, China). This cell line was originally
isolated from the surgical specimens of a Chinese man
with advanced lung adeno-carcinoma by Shanghai Chest
Hospital and Cellular Institute of Chinese Academy of
Science in 1980[15]. The cells were cultured at 37°C
under a 5% CO2  atmosphere in Dulbecco's Modified
Eagle's Medium (DMEM) supplemented with 10% fetal
bovine serum (FBS, Hyclone, UT), 100 U/ml penicillin,
and 100 μg/ml streptomycin. Cells were regularly certi-
fied as free of Mycoplasma contamination.
Animal experiments
Five- to 6-week-old male congenitally immune-deficient
nonobese diabetic/severe combined immune-deficient
( N O D / S C I D )  m i c e  w e r e  m a i n t a i n e d  u n d e r  s p e c i f i c
pathogen-free (SPF) conditions. Mice were manipulated
and housed according to protocols approved by the
Shanghai Medical Experimental Animal Care Commis-
sion. To isolate a highly metastatic cell line, briefly, 2.0 ×
106 of the SPC-A-1 cells were injected subcutaneously
(s.c) into NOD/SCID mice. When the subcutaneous
tumour developed, small pieces of tumour tissue were
implanted into the s.c. sites of mice in the first generation
of mouse models and the primary tumours were excised 4
weeks later. Those mice were sacrificed under deep anes-
thesia when they showed signs of distress, and visual lung
metastases were isolated and s.c. implanted into the new
recipient mice in the second generation of mouse models
for in vivo selection. These procedures (lung metastasis,
s.c. implantation, lung metastasis) were repeated for three
rounds. At the end of the selection, the lungs harboring
massive metastatic lesions were isolated and s.c.
implanted into new recipient mice, after which the pri-
mary tumour was removed to initiate in vitro primary
culture.
Subcutaneous tumour implantation was performed as
described [15]. In brief, an SPC-A-1 flank-grown tumour
was removed from a NOD/SCID mouse and was rinsed
and minced in cold phosphate-buffered saline (PBS). The
tumour was implanted by the s.c. injection of minced
tumour tissue suspended in PBS using a 1 cc tuberculin
syringe and an 18-gauge needle.
For primary tumour growth assays and spontaneous
metastasis  via s.c. injection, cells (2 × 106 per mouse)
were injected subcutaneously into the right upper flank
region of NOD/SCID mice. Mice were monitored weekly
for tumour size and evidence of morbidity related to the
primary tumour or metastases. Tumour size was quanti-
fied in two dimensions using calipers. Tumour volume
was calculated as follows: tumour volume (mm3) = L × W
× W/2, where L represents length and W represents
width. Nine weeks later, all mice were sacrificed, and the
organs, including lungs and livers, were removed and
processed for standard histological studies. For histologi-
cal analysis, the primary tumours and mouse organs were
harvested at necropsy and fixed in 10% formalin. The
fixed samples were then embedded in paraffin, and three
non-sequential serial sections were obtained per animal.
The sections were stained with H&E and analyzed for the
presence of metastases.
Transduction of tumour cells
The GFP-Luc lentiviral vector encoding a fusion gene of
GFP and luciferase was generated by inserting the GFP-
Luc gene from the plasmid eGFP-2A-CBGr99 (kindly
provided by Professor Hammerling) into the BamHI/
XhoI sites of a pWPXL vector (Addgene). Transductions
of SPC-A-1sci and SPC-A-1 cells were performed with
the aforementioned lentiviral vector according to instruc-
tions supplied by Addgene http://www.addgene.org andJia et al. BMC Cancer 2010, 10:364
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stable transfectants were further isolated by cell sorting
(Epics Altra, Beckman Coulter) on the basis of their
EGFP expression.
shRNA experiments
The lenti-virus shRNA vector was constructed as
described previously [16]. Briefly, Fibronectin and nega-
tive control shRNA were subcloned into the MluI/ClaI
sites of a pLVTHM vector (Addgene) with the following
oligonucleotides respectively: 5'-CGCGTCG GCCCGGT
TGTTATGACAATTTttcaagagaAAATTGTCATAAC AA
CCGGGCTTTTTTGGAAT-3'and 5'-CGATTCCA AAA
AAGCCCGGTTGTTATGACA ATTTtctcttgaaAA ATT-
GTCATAACAACCGGGCCGA-3' for Fibronectin, and
5'-CGCGTCGTAGCGACTAAACACATCAATTttc aaga
gaAATTGATGTGTTTAGTCGCTATTTTTTGGA AT-
3' and 5'-CGATTCCAAAAAATAGCGACTAAACACAT
CAATTtctcttgaaAATTGATGTGTTTAGTCGCTACGA-
3' for the negative control. Lenti-virus generation and
infection of SPC-A-1sci cells were performed as
described above. For experimental metastasis in vivo,
SPC-A-1sci cells (2 × 106 per mouse) stably expressing
shRNA against fibronectin or negative control were
injected into the tail vein of NOD/SCID mice (n = 8).
Four weeks later, the mice were sacrificed and the lungs
were removed and processed for histological examina-
tion.
Luciferase imaging and GFP imaging
We used a Berthold LB983 NightOwl System (EG&G
Berthold, Bad Wildbad, Germany) to monitor the pri-
mary tumour growth and distant metastasis of SPC-A-
1sci and SPC-A-1 cells in mouse models as previously
described [17,18]. For in vivo bioluminescence imaging
(in vivo BLI), the animals were injected i.p. with 150 mg
luciferin (Luciferin-EF, Promega) per kg of body weight,
anesthetized with pentobarbital (10 mg/ml) in sterile
water, and then placed in the NightOwl LB 983 Molecular
Light Imager. For ex vivo biofluorescence imaging (ex vivo
BFI), mice lungs were excised after in vivo BLI and placed
in the chamber of the NightOwl LB 983 Molecular Light
Imager and imaged.
Immunofluorescence and immunohistochemical analysis
The experiments were performed as described previously
[19]. For indirect immunofluorescence analysis, cells
were plated and grown on glass slides for 18~20 hours
and fixed with 4% paraformaldehyde. The slides were
then blocked and incubated with the following primary
antibodies: Anti-E-cadherin and ZO-1 were obtained
from Santa Cruz (1:50), anti-Vimentin from DAKO
(1:100), anti-Fibronectin from Abcam (1:100) and anti-α-
tubulin and DAPI were obtained from Sigma (1:100).
Finally, the slides were incubated with fluorescence con-
jugated secondary antibody (Sigma) and viewed with a
Fluoview FV1000 microscope (Olympus, Japan).
For immunohistochemical analysis, all tissue samples
were fixed in phosphate-buffered neutral formalin,
embedded in paraffin, and cut into 5-μm-thick serial sec-
tions. Immunohistochemical staining with antibodies to
E-cadherin (1:50, Santa Cruz), Vimentin (1:25, DAKO)
was performed according to standard procedures. Results
were observed and photographed with an Axioskop 2
microscope (Carl Zeiss, Oberkochen, Germany) and
DP70 Imaging system (Olympus, Japan).
Soft agar colony formation assay
Colony formation in soft agar was assayed as described
previously [20]. Briefly, SPC-A-1sci or SPC-A-1 cells
(1000 cells/well) were seeded in 0.3% agar (Sigma) con-
taining culture medium layered on 0.5% agar medium
(0.3 ml/well) in 24-well plates and cultured at 37°C under
5% CO2 for three weeks. The colonies formed were pho-
tographed with an Axioskop 2 microscope (Carl Zeiss,
Oberkochen, Germany) and DP70 Imaging system
(Olympus, Japan). Pictures of three random fields in each
well were obtained from three replicate, and the number
of colonies was counted.
In vitro wound healing assay
The experiment was performed as described previously
w i t h  l i t t l e  m o d i f i c a t i o n  [ 2 0 ] .  C e l l s  w e r e  c u l t u r e d  o n
Fibronectin-coated or uncoated 24-well plates in com-
plete medium. Upon reaching confluence, the complete
medium was replaced with conditioned medium (1% FBS
DMEM) for an additional 24 h, and then the cell mono-
layer was wounded with 200 μL tips. The cells were then
cultivated and photographed with a CKX41 microscope
(Olympus, Japan) for another 24 h in the conditioned
medium. The percent wounded area filled was calculated
as follows: {(mean wounded breadth - mean remained
breadth)/mean wounded breadth} × 100 (%).
Migration and invasion assays
Cell migration and invasion assays were performed using
6.5-mm trans-well chambers (8 μm pore size, Corning) as
described previously with some modifications [21]. Cells
were seeded at 25,000 cells per well into trans-well cham-
bers for migration assays or at 100,000 cells per well into
Matrigel-coated trans-well chambers. The wells were
washed with PBS after 16 h for migration assays or after
24 h for invasion assays. The cells that had migrated to
the basal side of the membrane were fixed and stained
with H&E or crystal violet, visualized and photographed
with a CKX41 microscope (Olympus, Japan) at 400×
magnification and DP20 Imaging system (Olympus,
Japan). Pictures of three random fields from three repli-
cate wells were obtained, and the number of cells that had
migrated was counted.Jia et al. BMC Cancer 2010, 10:364
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Cell spreading assay
The experiments were performed as previously described
[21] with some modifications. Briefly, 24-well plates were
pre-coated or uncoated overnight at 4°C with 10 μg/mL
Human Fibronectin (Sigma) in PBS. The coated wells
were washed with PBS and blocked with 1% BSA in PBS
for an additional hour. Aliquots of cells (1.0 × 105) were
applied to wells for various time points. After each time
point, the wells were washed twice with PBS, and then
the adherent cells were visualized and photographed with
a CKX41 microscope (Olympus, Japan) at 200 × magnifi-
cation and DP20 Imaging system (Olympus, Japan).
Real-time quantitative PCR analysis
Total RNA of cultured SPC-A-1sci and SPC-A-1 cells
were isolated using Trizol reagents (Invitrogen) according
to the manufacturer's instructions. First-strand cDNA
synthesis and amplification were performed using
Reverse Transcription Reagents (Takara) following the
manufacturer's instructions. Real-time PCR was carried
out using a 7300 Real-Time PCR System with SDS RQ
Study software (Applied Biosystems) according to the
manufacturer's instructions. cDNA templates were com-
bined with SYBR Green premix with Rox (Takara) to per-
form quantitative-PCR reactions. Primers used for
quantitative-PCR were as follows: E-cadherin forward: 5'-
TGGCTTCCCTCTTTCATC-3'; E-cadherin reverse: 5'-
GTTCCGCTCTGTCTTTGG-3'; Fibronectin forward:
5'-GGAGTTTCCTGAGGGTTT-3'; Fibronectin reverse:
5'-GCAGAAGTGTTTGGGTGA-3'; Vimentin forward:
5'-CTGAACCTGAGGGAAACTAA-3'; Vimentin
reverse:5'-AGAAAGGCACTTGAAAGCT-3'; β-actin
forward: 5'-AGTGTGACGTGGACATCCGCAAAG-3';
β-actin reverse: 5'-ATCCACATCTGCTGGAAGGTG-
GAC-3'. Gene expression was normalized to β-actin. All
reactions were run in triplicate.
Immunoblotting assay
Cells were lysed and proteins were detected as described
previously [10]. Immunoblotting was carried out with the
anti-Fibronectin (Abcam, 1:400) and the β-actin antibody
was obtained from Sigma (1:15000).
Statistics
Data are presented as the means ± SD and were evaluated
with Student's t-test. P < 0.05 was accepted as statistically
significant.
Results
In vivo selection of highly metastatic human lung cancer 
cells
To develop an advanced metastatic model of lung cancer,
we derived a highly metastatic human lung cancer cell
line (named SPC-A-1sci) using the poorly metastatic
human cell line SPC-A-1 as a starting point (Fig. 1A). The
method used is similar to that described previously for
generating a metastatic model of breast cancer [22].
Briefly, in order to get pulmonary metastatic nodules for
further  in vivo selection, we removed the s.c. primary
tumour from tumour-bearing mice to allow sufficient
time for distant micrometastases to grow into macrome-
tastases in the first generation of mouse models. Through
three rounds of in vivo serial selection, the incidence of
lung metastasis reached 100% in the fourth generation of
the mouse model (Table 1), from which massive meta-
static lesions were isolated (Fig. 1B) and s.c. implanted
into new recipient mice, and the primary tumour was
adapted to tissue culture for the generation of the SPC-A-
1sci cell line.
To further characterize in vivo behaviors of this cell
line, we engineered SPC-A-1sci and its parent SPC-A-1
cells with dual reporters of GFP and Luciferase and mon-
itored them in NOD/SCID mice by optical imaging tech-
niques. As shown in Fig. 1C, we could not only detect the
primary tumour growth of SPC-A-1sci cells by in vivo
bioluminescence imaging weekly, but also observe the
pulmonary metastases by ex vivo fluorescence imaging in
one sacrificed animal at week 7 and week 8. Subsequently,
numerous metastases could be detected at week 9 in all
remaining mice of this group when they displayed signs
of being moribund. This was significant compared with
the SPC-A-1 group, in which no fluorescence signals of
pulmonary metastasis could be monitored at the same
end-point when they still displayed an active status (data
not shown). Briefly, we successfully developed a highly
metastatic cell line from a poorly metastatic lung cancer
Table 1: Incidence of pulmonary metastasis in each generation of mouse model during in vivo selection
Generation Macrometastases
(mouse numbers)
Micrometastases
(mouse numbers)
Selection periods (weeks)
First 2/10 6/10 18
Second 1/7 5/7 14
Third 3/9 7/9 13
Fourth 5/9 9/9 12Jia et al. BMC Cancer 2010, 10:364
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SPC-A-1 cell line. Whereas the parental line SPC-A-1
required 14 weeks (post-primary tumour resection) for
the formation of visible metastatic nodules in lungs, the
SPC-A-1sci required only 7 weeks for the formation of
large macroscopic nodules in the lungs.
SPC-A-1sci cells display phenotypic changes consistent 
with EMT
The generation of motile, invasive carcinoma cells was
recently found to share some of the key morphologic and
molecular characteristics of EMT [23]. As shown in Fig.
2A, distinct morphological differences between the SPC-
A-1sci cell line and its parental SPC-A-1 cell line were
observed in cell culture. Whereas SPC-A-1 cells are
polygonal and grow in cobblestone clusters, SPC-A-1sci
cells are elongated and spindle-shaped, and grow in a
scattering pattern to confluence. In addition, the
cytoskeleton α-tubulin has also been reorganized in SPC-
A-1sci cells, exhibiting the appearance of regular stretch-
ing and dispersion by immunofluorescence staining; this
is not the case with SPC-A-1 cells (Fig. 2B).
This morphological change is one of the hallmarks of
EMT. To determine whether the molecular alterations of
EMT occurred in these cells, we examined the localiza-
tion of several adherent junction proteins, such as E-cad-
herin and ZO-1, by confocal immunofluorescence
staining. The results showed that the two proteins almost
disappear from the cell membrane in the SPC-A-1sci cells
but show strong membrane staining in their parent SPC-
A-1 cells (Fig. 2B). However, the expression levels of E-
cadherin have no significant difference between SPC-A-
1sci and SPC-A-1 cells by quantitative PCR analysis (Fig.
2C). Furthermore, immunohistochemical staining of s.c.
primary tumours of SPC-A-1sci cells also confirmed the
remarkably reduced expression of E-cadherin (Fig. 2D).
In contrast, the expression of mesenchymal markers,
including vimentin and fibronectin, whose expression has
been shown to positively correlate with the EMT, was
strongly increased in SPC-A-1sci cells (Fig. 2B-D).
EMT could be a reversible, dynamic process and may
be regulated by the tumour microenvironment, carci-
noma cells that have undergone EMT during invasion
seem to regain their epithelial characteristics at the meta-
static sites [24]. As shown in Fig. 2D, by immunohis-
tochemical analysis, the membrane staining of the
epithelial marker E-cadherin significantly increased in
Figure 1 In vivo selection of highly metastatic human lung cancer cells. A, In vivo selection scheme. Parental human SPC-A-1 lung cancer cells 
were subcutaneously injected into NOD/SCID mice. When the subcutaneous tumour developed, small pieces of tumour tissue were implanted into 
the s.c. sites of new recipient mice in the first generation of mouse models, and primary tumours were excised 4 weeks later. Fourteen weeks after 
resection, visual lung metastases were isolated and re-implanted into the s.c. region of new recipient mice for in vivo selection. Finally, after three 
rounds of in vivo seleciton, tumour nodules were isolated from the lungs harboring massive metastatic lesions and s.c. implanted into new recipient 
mice, after which the primary tumour was removed to initiate in vitro culture and the SPC-A-1sci cell line was derived. B, Representative images of 
visual inspection of one mouse lungs for the presence of gross tumour nodules (arrows indicate) in the fourth generation. C, Representative biolumi-
nescence images taken from the ventral side of the mice by in vivo BLI (upper) for primary tumour growth, and fluorescence images taken from the 
lungs of one sacrificed mouse by ex vivo BFI (lower) for spontaneous metastasis at three sequential time points from week 7 to 9, at 1-week intervals, 
after s.c. injection with GFP-Luc transduced SPC-A-1sci cells.Jia et al. BMC Cancer 2010, 10:364
http://www.biomedcentral.com/1471-2407/10/364
Page 6 of 12
Figure 2 SPC-A-1sci cells display distinct phenotype consistent with EMT. A, Representative phase-contrast images of SPC-A-1sci and SPC-A-1 
cells are shown. Magnification, 200×. B, Immunofluorescence staining of α-tubulin, E-cadherin, ZO-1, Vimentin and Fibronectin in SPC-A-1sci cells and 
SPC-A-1cells. The green/red signal represents the staining of the indicated proteins, and the blue signal represents the nuclear DNA staining by DAPI. 
Magnification, 600×. C, Quantitative-PCR analysis of the mRNA levels of E-cadherin, Vimentin and Fibronectin in SPC-A-1sci and SPC-A-1 cells. Results 
are expressed as mean ± SD; **, P < 0.01; *, P < 0.05. D, Expression of E-cadherin and vimentin were examined by immunohistochemical staining of 
serial sections from s.c. primary tumours of SPC-A-1 cells, SPC-A-1sci cells and also pulmonary metastatic nodules of SPC-A-1sci cells. Magnification, 
200×.Jia et al. BMC Cancer 2010, 10:364
http://www.biomedcentral.com/1471-2407/10/364
Page 7 of 12
the pulmonary metastatic nodules compared to the pri-
mary SPC-A-1sci tumour, and otherwise the mesenchy-
mal marker, vimentin, remarkably decreased in the
pulmonary metastatic nodules. Hence, both the morpho-
logical and molecular changes in SPC-A-1sci cells dem-
onstrated that they had undergone an EMT program.
SPC-A-1sci cells acquire increased potentials of migration 
and invasion
Cell proliferation and colonization are among the neces-
sary functions required for metastatic progression of
tumour cells. However, the SPC-A-1sci cells are not more
aggressive than the parental population in the prolifera-
tion in culture and formation of subcutaneous tumours
(Fig. 3A-C). This suggests that the increased metastatic
activity of SPC-A-1sci cells does not result from a faster
growth rate, but rather from the acquisition of other
metastasis-promoting functions.
We next took steps to characterize other cellular prop-
e r t i e s  t h a t  m i g h t  b e  r e l e v a n t  t o  m e t a s t a s i s .  F i r s t ,  w e
employed wound healing assays to determine migratory
abilities of SPC-A-1sci and SPC-A-1 cells on fibronectin
coated or uncoated plates. As shown in Fig. 3D, SPC-A-
1sci cells healed the wound dramatically faster than their
parent cells did. It's worthy to note that this effect is not
s u b s t r a t e  d e p e n d e n t ,  a s  S P C - A - 1 s c i  c e l l s  a l s o  h a v e  a n
increased migratory ability on non-coated plate (data not
shown). Importantly, when seeded on fibronectin-coated
plate in this experiment, the poorly metastatic SPC-A-1
Figure 3 SPC-A-1sci cells acquire increased potentials of migration and invasion. A, In vitro growth curves of SPC-A-1sci and SPC-A-1 cells, cells 
(2 × 104/well) were cultured in 24-well plates, after which cells were trypsined and counted at indicated times. Results are expressed as mean ± SD; *, 
P < 0.05. B, Soft agar colony formation of SPC-A-1sci and SPC-A-1 cells, cells (1 × 103/well) were cultured in 24-well plates, colonies were photographed 
and counted after three weeks. Results are expressed as mean ± SD; *, P < 0.05. C, In vivo growth curve of SPC-A-1sci and SPC-A-1 cells, cells (2.0 × 106 
per mouse) were s.c. implanted into NOD/SCID mice, after which the tumour volume was measured over time. Results are expressed as mean ± SD. 
C, Motility activities of SPC-A1sci and SPC-A-1 cells were determined by wound healing assays Confluent monolayers of SPC-A1sci and SPC-A-1 cells 
in fibronectin coated 24-well plates were wounded by scratching, after which the wells were washed, incubated with conditioned medium for 24 h 
and photographed (lower). Motility was assessed on the basis of percentage of wounded area filled in (upper). Results are expressed as mean ± SD; 
**, P < 0.01. D and E, Trans-well migration and invasion assays of SPC-A-1sci and SPC-A-1 cells For migration assay (D), cells (2.5 × 104/well) were seeded 
into non-coated trans-well plates and culture for 16 h at 37°C; for invasion assays (E), cells (1.0 × 105/well) were seeded into Matrigel-coated trans-well 
plates and cultured for 24 h at 37°C, after which cells that had migrated or invaded to the underside of the inserts were stained with H&E and the cells 
on each insert were photographed (lower) and quantified (upper) at 400× magnification. All experiments were repeated thrice; Results are expressed 
as mean ± SD; *, P < 0.05.Jia et al. BMC Cancer 2010, 10:364
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cells rapidly spread and show significantly morphologic
changes. Subsequently, we also found that SPC-A-1sci
cells were more randomly motile than their parent cells
by trans-well migration assay (Fig. 3E). Furthermore, we
determined the invasive abilities of SPC-A-1sci and SPC-
A-1 cells by trans-well invasion assays, and it was found
that significantly more SPC-A-1sci cells invaded to the
basal side of the membrane than SPC-A-1 cells did (Fig.
3F). These data suggested that the SPC-A-1sci cells
acquire enhanced abilities to migrate and invade, which
may be associated with their highly metastatic behavior
in vivo.
Fibronectin promotes SPC-A-1sci cell invasion and 
metastasis
As described above, fibronectin could promote the
spreading of the parent SPC-A-1 cells. We therefore
examined the spreading ability of SPC-A-1sci and SPC-
A-1 cells after plating on fibronectin coated or uncoated
plates and found that SPC-A-1sci cells spread signifi-
cantly faster than SPC-A-1 cells did on both conditions
(Fig. 4A). Importantly, SPC-A-1 cells spread rapidly and
exhibited distinct morphologic changes that are similar
to SPC-A-1sci cells when they were cultured on fibronec-
tin coated plates but not on uncoated plates, such as elon-
gated shape and increased migratory protrusions;
whereas SPC-A-1sci cells showed little difference
between the two conditions and maintained their mesen-
chymal phenotype. These findings suggested that
fibronectin play a crucial role in promoting cytoskeleton
reorganization and morphological transition from SPC-
A-1 to SPC-A-1sci cells. In order to confirm the direct
effects of fibronectin on cell migration and invasion of
S P C - A - 1 s c i  c e l l s ,  w e  u s e d  s h R N A  t o  k n o c k d o w n  t h e
expression of fibronectin (Fig. 4B) and then measured the
migratory and invasive abilities of SPC-A-1sci cells by
trans-well assays. The results showed that knockdown of
fibronectin significantly decrease the migration and inva-
sion of SPC-A-1sci cells (Fig. 4C-D). Furthermore, the in
vivo metastasis assays demonstrated the similar results.
As shown in Fig. 5, not only the incidence (3/8) but also
the number of lung metastatic nodules significantly
decreased in mice inoculated with shRNA-Fn1 cells com-
pared to shRNA-NC cells (8/8). These findings suggested
a functional role of fibronectin in the SPC-A-1sci cell
invasion and metastasis.
Discussion
Metastasis, the foremost cause of mortality in cancer
patients, accounts for more than 90% of all deaths in solid
tumour diseases, but the underlying mechanisms remain
elusive. Recently, a combination of tumour model sys-
tems and microarray profiling technologies has been
proved to be effective in identifying relevant genes and
pathways for tumour metastasis [4,25]. However, most
metastatic models are derived via direct injection of can-
cer cells into the circulation of mice, which puts the focus
on end-stage metastatic cells. These models are thus
likely to miss the essential genes and pathways required
for the early steps of metastasis, including EMT, migra-
tion, invasion, and intravasion. It is therefore necessary to
develop spontaneous metastatic models that faithfully
mimic the selection and evolution of metastasis in human
tumours.
Human tumours rarely metastasize from a primary
tumour site in immune-deficient mice when they are
transplanted into an ectopic site for the particular type of
tumour being analyzed. Orthotopic implantation has
been proved to be a better approach for the development
of metastasis models[26]. Unlike breast cancer and mela-
noma, however, it is not easy to develop an orthotopic
model for lung cancer because of the relative inaccessibil-
ity of anatomic location. Fortunately, s.c. tumour implan-
tation has been widely used for the majority of human
tumour models [27,28], and growing evidence shows that
the incidence of metastasis can be greatly promoted by
resection of primary tumours in s.c. transplantation mod-
els [22,29]. It is widely believed that metastatic cells are
rare and that they evolve during the late stages of tumour
progression from a series of genetic changes that enable
the cells to progress through the sequential steps that
finally result in growth in distant organ microenviron-
ments [30,31]. Recently, increasing evidence has shown
that highly metastatic cells have already existed in their
parent cell lines or primary tumours, and the mouse
could be used as a "cell sorter" to select for these cells
[29,32]. In this study, we successfully isolate a highly met-
astatic cell line from a poorly metastatic lung cancer SPC-
A-1 cell line by in vivo selection combined with resection
of primary tumours in mice.
Growing evidence suggests that EMT has an important
role in tumour metastasis [5,25]. The essential features of
EMT are the disruption of intercellular contacts and the
enhancement of cell motility, thereby leading to the
release of cells from the parent epithelial tissue. The
resulting mesenchymal-like phenotype is suitable for
migration and thus for tumour invasion and dissemina-
tion, allowing metastatic progression to proceed. In this
study, we show that SPC-A-1sci cells display morphologic
changes consistent with EMT, and that some molecular
alterations have taken place in these cells, such as loss of
E-cadheirn from the cell membrane of SPC-A-1sci cells.
Of note, there is no significant difference in the mRNA
level of E-cadherin between SPC-A-1sci and SPC-A-1
cells. E-cadherin mainly binds to plasma membrane to
mediate cell-cell interactions, when the membrane bind-
ing was destroyed through cleavage by γ-secretase or
other proteases[33-35], the functions of E-cadherinJia et al. BMC Cancer 2010, 10:364
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would be lost even if the expression levels of it has no
changes. Moreover, EMT is a reversible program, and
carcinoma cells that have acquired a mesenchymal phe-
notype can revert to an epithelial state via a MET [36,37].
In the sequential cascade of tumour metastasis, EMT has
a positive role in the majority of earlier stages; however,
when the disseminating cells arrive in the microenviron-
ment of their targeted organs, the mesenchymal pheno-
type is not effective in colonizing and growing into
macrometastases, such that MET is required in these
later stages in order to revert to an epithelial state. Our
data show that, to some extent, the expression levels of
some EMT markers became switched between the pul-
monary metastatic nodules and the primary SPC-A-1sci
tumour, as determined by immunohistochemical analy-
sis. Those results indicate that SPC-A-1sci cells undergo
EMT, which may be associated with the metastatic
potential of SPC-A-1sci cells, including the enhancement
of cell motility, invasion, and adhesion. However, a re-dif-
ferentiation towards an epithelial phenotype, resembling
a MET, is also required for the formation of pulmonary
metastatic nodules in the end. These data therefore indi-
c a t e  t h a t  m a l i g n a n t  p r o g r e s s i o n  o f  S P C - A - 1 s c i  c e l l s  i s
based on a dynamic process. A large body of literatures
indicated that increased cell migration and invasion are
functional hallmarks of EMT and are also important
steps during the cascade of tumour metastasis [38]. Here,
w e  s h o w e d  t h a t  S P C - A - 1 s c i  c e l l s  a r e  m o r e  a g g r e s s i v e
than their parental cells in vitro. The potentials of cell
motility, migration and invasion are greatly increased in
SPC-A-1sci cells. These results suggested that SPC-A-
1sci cells acquire the increased abilities to migrate and
Figure 4 Fibronectin promotes SPC-A-1sci cell invasion and metastasis. A, Representative phase-contrast images of SPC-A-1sci and SPC-A-1 cells 
4 hours after seeded on fibronectin coated or uncoated plates in cell spreading assays. Magnification, 200×. B, Immunoblotting detection of fibronec-
tin in SPC-A-1sci cells infected with shRNAs against fibronectin (shRNA-Fn1) or negative control (shRNA-NC) as indicated. β-actin was used as a loading 
control. C and D, Trans-well migration and invasion assays for SPC-A-1sci cells infected with shRNAs against fibronectin (shRNA-Fn1) or negative con-
trol (shRNA-NC) as indicated. All experiments were repeated thrice; Results are expressed as mean ± SD; *, P < 0.05.Jia et al. BMC Cancer 2010, 10:364
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invade, which further demonstrated that SPC-A-1sci cells
have undergone EMT.
The complex interactions between tumour cells and
extracellular matrix play important roles in mediating
and regulating many processes during tumour metastasis,
including cell migration, cytoskeleton reorganization and
morphologic transition [39,40]. Fibronectin is an extra-
cellular matrix glycoprotein that plays major roles in cell
differentiation, growth and migration, being involved in
processes such as wound healing and embryonic develop-
ment as well as oncogenic transformation [11,41]. In this
study, we showed that SPC-A-1sci cells express higher
level of fibronectin, and down-regulation of which can
significantly decrease both the in vitro and in vivo meta-
static abilities of those cells. Furthermore, fibronectin is
also a mesenchymal maker, whose expression positively
correlates with EMT [25]. But the contributing roles and
precise mechanisms of fibronectin in EMT are still
unknown. In this report, we found that fibronectin can
induce the poorly metastatic SPC-A-1 cells to take on
morphological changes that are similar to SPC-A-1sci
cells and also typical of EMT. Briefly, these findings sug-
gested that fibronectin play a crucial role in the highly
metastatic behavior of SPC-A-1sci cells.
Conclusions
In summary, we have successfully established a reproduc-
ible  s.c. mouse model and isolated a highly metastatic
human lung adeno-carcinoma cell line by in vivo selec-
tion in NOD/SCID mice. The new cell line, SPC-A-1sci,
possessed highly metastatic potentials and undergone an
EMT program, which may be associated with increased
expression of fibronectin. To the best of our knowledge, it
is the first in the literature that reports the presence of
EMT in lung cancer and the functional roles of fibronec-
tin in lung cancer cell invasion and metastasis based on
an in vivo tumour metastasis model. This model may pro-
vide a platform to identify elements that are important in
the process of metastasis and to learn how they contrib-
ute functionally to the biology of lung cancer metastasis.
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